Literature DB >> 14512786

The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells.

Wojciech Placha1, Dorota Gil, Aldona Dembińska-Kieć, Piotr Laidler.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor family of ligand-activated transcription factors. PPARgamma ligands have been shown to inhibit the growth of cells from different cancer lineages. This study was designed to evaluate the effects of PPARgamma receptor activation in human melanoma cell lines. The effects of its expression and activation on cell proliferation and apoptosis in human melanoma cell lines (early stage cancer [WM35] and metastatic tumour [A375]) were investigated. Reverse transcription-polymerase chain reaction and Western blot analysis showed that both human melanoma cell lines expressed PPARgamma mRNA and protein. Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene. Ciglitazone and PGJ2 inhibited melanoma cell proliferation in a dose-dependent manner. Analysis of the cellular morphology and apoptosis assayed by fluorescence microscopy after incubation of A375 cells with 10 micro M ciglitazone for 24 h indicated that this ligand not only inhibited cell proliferation but also induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512786     DOI: 10.1097/00008390-200310000-00003

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  10 in total

1.  Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Authors:  T Botton; A Puissant; Y Cheli; T Tomic; S Giuliano; L Fajas; M Deckert; J-P Ortonne; C Bertolotto; S Tartare-Deckert; R Ballotti; S Rocchi
Journal:  Cell Death Differ       Date:  2010-07-02       Impact factor: 15.828

Review 2.  Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism.

Authors:  Maja Grabacka; Malgorzata Pierzchalska; Krzysztof Reiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

Review 3.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

4.  PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.

Authors:  Maja Grabacka; Wojciech Placha; Krystyna Urbanska; Piotr Laidler; Przemysław M Płonka; Krzysztof Reiss
Journal:  Pigment Cell Melanoma Res       Date:  2008-04-26       Impact factor: 4.693

5.  PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells.

Authors:  Linda L Eastham; Caroline N Mills; Richard M Niles
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

6.  Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.

Authors:  Michael G Borland; Pei-Li Yao; Ellen M Kehres; Christina Lee; Amanda M Pritzlaff; Elizabeth Ola; Ashley L Wagner; Brooke E Shannon; Prajakta P Albrecht; Bokai Zhu; Boo-Hyon Kang; Gavin P Robertson; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2017-10-01       Impact factor: 4.849

7.  Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.

Authors:  Joshua P Klopper; Vibha Sharma; Andrew Berenz; William R Hays; Michele Loi; Umarani Pugazhenthi; Sherif Said; Bryan R Haugen
Journal:  Mol Cancer       Date:  2009-03-06       Impact factor: 27.401

8.  Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.

Authors:  Verena Paulitschke; Silke Gruber; Elisabeth Hofstätter; Verena Haudek-Prinz; Philipp Klepeisz; Nikolaus Schicher; Constanze Jonak; Peter Petzelbauer; Hubert Pehamberger; Christopher Gerner; Rainer Kunstfeld
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

9.  The Critical Role of PPARgamma in Human Malignant Melanoma.

Authors:  Christian Freudlsperger; Udo Schumacher; Siegmar Reinert; Jürgen Hoffmann
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma.

Authors:  Stefanie Meyer; Thomas Vogt; Michael Landthaler; Anna Berand; Albrecht Reichle; Frauke Bataille; Andreas H Marx; Anne Menz; Arndt Hartmann; Leoni A Kunz-Schughart; Peter J Wild
Journal:  PPAR Res       Date:  2009-07-20       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.